Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EUTHROID-3 vs YUTOPAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
EUTHROID-3 is a combination of liothyronine (T3) and levothyroxine (T4) that supplements endogenous thyroid hormone. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the cell nucleus, modulating gene transcription and increasing metabolism, protein synthesis, and oxygen consumption.
Selective beta-2 adrenergic receptor agonist; relaxes uterine smooth muscle by increasing intracellular c AMP, reducing myosin light chain kinase activity and inhibiting uterine contractions.
Hypothyroidism (thyroid hormone replacement therapy),Thyroid-stimulating hormone suppression in thyroid cancer (off-label)
FDA: Management of preterm labor in pregnant women between 20 and 36 weeks gestation without medical or obstetric contraindications.,Off-label: Tocolysis for cervical cerclage, external cephalic version, acute tocolysis prior to emergency cesarean section.
Levothyroxine/liothyronine combination (EUTHROID-3): 1 tablet (50 mcg levothyroxine, 15 mcg liothyronine) orally once daily, adjusted based on TSH levels.
Initial dose of 50 mcg/min IV, increased by 50 mcg/min every 10-20 minutes until uterine contractions cease or maximum of 350 mcg/min is reached. Maintenance at the lowest effective dose for 12-24 hours after contractions stop.
L-T4: 6-7 days; L-T3: 1-2 days. Clinical context: Steady-state achieved in ~6 weeks for T4, ~8 days for T3.
1.7-2.5 hours (terminal); increased in renal impairment.
Levothyroxine (T4) is metabolized to liothyronine (T3) via deiodination in peripheral tissues (liver, kidney, etc.). Liothyronine (T3) is metabolized via deiodination and conjugation (glucuronidation and sulfation) in the liver and kidneys. Hepatic enzymes involved include deiodinases (D1, D2) and UDP-glucuronosyltransferases (UGTs).
Primarily hepatic via conjugation (glucuronidation and sulfation) and CYP450 isoenzymes (CYP3A4, CYP2D6).
Renal (approx. 20-40% as unchanged drug and metabolites), biliary/fecal (approx. 60-80% as conjugated metabolites).
Primarily renal (90-95% as unchanged drug and metabolites); less than 5% fecal.
99.8% for L-T4 (thyroxine-binding globulin, transthyretin, albumin); 99.7% for L-T3 (same proteins, lower affinity).
25-30% (primarily albumin).
L-T4: 0.1-0.2 L/kg (mainly intravascular); L-T3: 0.4-0.6 L/kg (broader tissue distribution).
0.3-0.5 L/kg; distributes mainly into extracellular fluid.
Oral L-T4: 80-90% (fasting; reduced by food and malabsorption). Oral L-T3: 95-100% (well absorbed).
Not applicable (only IV route used clinically).
No specific GFR-based dose adjustment required; monitor thyroid function in severe chronic kidney disease (GFR <30 m L/min/1.73 m²) as drug clearance may be reduced.
No specific dose adjustment is recommended; however, use with caution in patients with renal impairment as drug elimination may be reduced.
No specific adjustment for Child-Pugh class A or B; use with caution in Child-Pugh C due to reduced hepatic conversion, monitor TSH.
No specific dose adjustment is recommended; however, use with caution in patients with hepatic impairment due to potential for altered metabolism.
Not FDA-approved for children; adult dose not suitable. For hypothyroidism in children, use levothyroxine monotherapy at 25-50 mcg/day for ages 1-3 years, 50-100 mcg/day for ages 3-10 years, and 100-150 mcg/day for ages 10-16 years, adjusted per TSH.
Not indicated for pediatric use; safety and efficacy in children have not been established.
Start with lower dose: 25 mcg levothyroxine/7.5 mcg liothyronine (half tablet) orally once daily, titrate slowly every 4-6 weeks based on TSH, due to increased risk of cardiac adverse effects and altered metabolism.
Not indicated for use in elderly patients; specifically used for preterm labor in pregnant women.
None
None.
Cardiac toxicity (e.g., arrhythmias, angina, myocardial infarction) due to excessive thyroid hormone levels,Thyrotoxic crisis (thyroid storm) if overdosed,Adrenal insufficiency: may precipitate acute adrenal crisis in patients with adrenal insufficiency,Delayed bone maturation in children if overtreated,Interactions with anticoagulants (increased INR), oral antidiabetic agents (hyperglycemia), and catecholamines (sympathomimetic effects)
Maternal pulmonary edema, especially with multiple gestation or concurrent corticosteroids.,Maternal cardiac effects: tachycardia, myocardial ischemia, arrhythmias.,Fetal effects: tachycardia, hypoglycemia, hypocalcemia, ileus.,Hypokalemia due to beta-2 stimulation.,Paradoxical bronchospasm in asthmatics.
Untreated adrenal insufficiency,Thyrotoxicosis (any etiology),Acute myocardial infarction (recent),Hypersensitivity to any component
Hypersensitivity to ritodrine or any component.,Maternal cardiac disease (e.g., tachyarrhythmias, myocardial insufficiency, severe hypertension).,Preeclampsia/eclampsia.,Intrauterine infection (chorioamnionitis).,Fetal distress or death.,Placental abruption or hemorrhage.,Cervical dilation > 4 cm or rupture of membranes.
Take on an empty stomach with water. Avoid concurrent intake with high-fiber foods, walnuts, soybean flour, cottonseed meal, or calcium/iron supplements within 4 hours of dosing as they may reduce absorption.
Avoid high-sodium foods and excessive fluid intake to reduce risk of fluid retention and pulmonary edema. Limit caffeine-containing beverages, as they may exacerbate tachycardia. Grapefruit juice has no known interaction but should be consumed in moderation. Maintain a balanced diet with adequate potassium intake, as ritodrine can cause hypokalemia.
Liothyronine (T3) and levothyroxine (T4) are endogenous thyroid hormones. Inadequate maternal thyroid hormone levels are teratogenic. At therapeutic doses, no known teratogenic risk from exogenous thyroid hormone. Fetal thyroid function develops at 10-12 weeks; prior to that, fetus depends on maternal T4. Overdose may cause fetal thyrotoxicosis. First trimester: maternal hypothyroidism increases risk of miscarriage and neurodevelopmental deficits. Second/third trimester: overtreatment may cause fetal tachycardia and growth restriction. Postpartum: adjust dose to prevent maternal hypothyroidism.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. In humans, limited data; use only if clearly needed. Risk of maternal pulmonary edema and fetal tachycardia at high doses; monitor fetal heart rate.
Excreted in human milk in low amounts. T3 and T4 are endogenous hormones; exogenous administration results in minimal transfer. M/P ratio: not established for Euthroid-3, but for levothyroxine, M/P ratio ~0.001. Considered compatible with breastfeeding when used at recommended doses. Monitor infant for thyroid suppression (rare at maternal therapeutic doses).
Excreted in breast milk; concentration likely low. M/P ratio not reported. Caution advised; consider risk-benefit.
Pregnancy increases T4 clearance due to increased TBG and placental deiodination. Dose may need to increase by 20-50% as early as 4-6 weeks gestation. Start with increased dose of 30-50% of prepregnancy dose. Adjust based on TSH every 4-6 weeks. Typical dose increase: 30-50% above baseline. Liothyronine component may require adjustment; monitor free T3 if using T3 therapy. Postpartum: reduce dose back to prepregnancy level.
No standard dose adjustment for pregnancy per se. Dosing is based on tocolytic effect; titrate to minimum effective dose. Avoid if maternal tachycardia >140 bpm or hemodynamic instability.
Euthroid-3 is a combination of liothyronine (T3) and levothyroxine (T4) in a fixed 1:4 ratio. Monitor TSH, free T4, and free T3 levels to avoid iatrogenic hyperthyroidism. Adjust dose cautiously in elderly or cardiac patients. Use with caution in adrenal insufficiency as thyroid replacement can precipitate adrenal crisis.
YUTOPAR (ritodrine) is a beta-2 adrenergic agonist used for acute tocolysis. Monitor maternal heart rate and blood pressure closely; tachycardia >140 bpm may require dose reduction or discontinuation. Contraindicated in preeclampsia, eclampsia, and maternal cardiac disease. Concurrent use with corticosteroids (betamethasone) can increase risk of pulmonary edema. Administer IV with caution; limit fluid intake to 1500-2000 m L/day to reduce fluid overload risk. When switching to oral therapy, ensure overlapping IV and oral doses to maintain therapeutic levels.
Take exactly as prescribed, typically once daily on an empty stomach 30-60 minutes before breakfast.,Do not switch between different thyroid hormone products without consulting your doctor.,Report symptoms of hyperthyroidism (rapid heartbeat, chest pain, heat intolerance, excessive sweating) or hypothyroidism (fatigue, weight gain, cold intolerance).,Inform all healthcare providers you are taking this medication.,Store at room temperature away from light and moisture.
Report immediately any chest pain, shortness of breath, palpitations, or swelling of hands/feet.,Avoid sudden discontinuation; tapered dose reduction is necessary under medical supervision.,Limit fluid intake to prevent fluid overload; follow fluid restriction guidelines provided by your doctor.,Inform all healthcare providers you are taking this medication, especially before any surgery or emergency treatment.,Do not breastfeed while on this medication; use effective contraception during treatment.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EUTHROID-3 vs YUTOPAR, answered by our medical review team.
EUTHROID-3 is a Thyroid Hormone Replacement that works by EUTHROID-3 is a combination of liothyronine (T3) and levothyroxine (T4) that supplements endogenous thyroid hormone. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the cell nucleus, modulating gene transcription and increasing metabolism, protein synthesis, and oxygen consumption.. YUTOPAR is a Parathyroid Hormone Analog that works by Selective beta-2 adrenergic receptor agonist; relaxes uterine smooth muscle by increasing intracellular c AMP, reducing myosin light chain kinase activity and inhibiting uterine contractions.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EUTHROID-3 and YUTOPAR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EUTHROID-3 is: Levothyroxine/liothyronine combination (EUTHROID-3): 1 tablet (50 mcg levothyroxine, 15 mcg liothyronine) orally once daily, adjusted based on TSH levels.. The standard adult dose of YUTOPAR is: Initial dose of 50 mcg/min IV, increased by 50 mcg/min every 10-20 minutes until uterine contractions cease or maximum of 350 mcg/min is reached. Maintenance at the lowest effective dose for 12-24 hours after contractions stop.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EUTHROID-3 and YUTOPAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EUTHROID-3 is classified as Category C. Liothyronine (T3) and levothyroxine (T4) are endogenous thyroid hormones. Inadequate maternal thyroid hormone levels are teratogenic. At therapeutic doses, no known teratogenic ris. YUTOPAR is classified as Category C. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. In humans, limited data; use only if clearly needed. Risk of maternal pulmonary edema and fetal tachycard. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.